Dimethyl Fumarate in Multiple Sclerosis Patients: A Real World Study

Yıl 2022, Cilt: 8 Sayı: 2, 129 - 133, 31.05.2022

Tuncay Gündüz , Sevda Öztürk Erden , Mefküre Eraksoy Murat Kürtüncü

https://doi.org/10.30934/kusbed.1012701

Öz

Objective: In this study, we aimed to obtain efficacy and safety data in relapsing multiple sclerosis (MS) patients who used dimethyl fumarate (DMF).
Methods: The study was designed as an observational retrospective cohort study. The data of relapsing MS patients who were followed up in the Neurology Department of İstanbul Faculty of Medicine and used DMF between 2014 and 2021 were analyzed. The first EDSS (expanded disability status scale) worsening time, first relapse time, and first new MRI lesion time information was obtained after the onset of DMF, and no evidence of disease activity (NEDA-3) status was determined.
Results: A total of 126 MS patients (85 females, 41 males; 116 RRMS, 10 RPMS) were included in the study. DMF was discontinued at a higher rate in patients who used another treatment before DMF, who were progressive with relapse, and who had a longer duration of disease before DMF (p=0.002, p=0.03, and p=0.002). Of the 65 patients diagnosed with RRMS and RPMS with brain MRI data, 25% of them maintained NEDA-3 status during the follow-up period after DMF initiation. However, an EDSS score below three before DMF onset significantly prolonged the time to loss of NEDA-3 status, first attack, and first disability accumulation (p=0.008 for NEDA-3, HR=1.95).
Conclusion: The real-life data obtained in our study show a great deal of similarity with the current information. Our findings indicate that if DMF is started in patients with an EDSS score below 3, the risk of developing attacks, new lesions on brain MRI, and disability accumulation is reduced.

Anahtar Kelimeler

dimethyl fumarate, neuroimmunomodulation, magnetic resonance imaging

Multipl Skleroz Hastalarında Dimetil Fumarat: Bir Gerçek Yaşam Çalışması

Öz

Amaç: Çalışmamızda dimetil fumarat (DMF) kullanan ya da daha önce kullanmış olan ataklı multipl skleroz (MS) hastalarında etkinlik ve güvenlik verilerinin elde edilmesi amaçlandı.
Yöntem: Çalışma gözlemsel retrospektif kohort çalışması olarak tasarlandı. İstanbul Tıp Fakültesi Nöroloji Ana Bilim Dalında takip edilen ve 2014–2021 yılları arasında DMF kullanmış ataklı yineleyici (RRMS) ve ataklı progresif (RPMS) MS hastalarının verileri incelendi. Hastalarda DMF başlandıktan sonraki ilk genişletilmiş özürlülük durum ölçeği (EDSS) kötüleşmesi, ilk atak ve ilk yeni MRG lezyonu bilgileri elde edilerek hastalık aktivitesi olmaması durumu (NEDA-3) belirlendi.
Bulgular: Toplam 126 ataklı MS hastası (85 kadın, 41 erkek; 116 RRMS, 10 RPMS) çalışmaya dahil edildi. DMF öncesi başka bir tedavi kullanmış olan, ataklı progresif olan ve DMF öncesi hastalık süresi daha uzun olan hastalarda DMF daha yüksek oranda kesilmişti (p=0,002, p=0,03 ve p=0,002). Beyin MRG bilgisi olan 65 RRMS ve RPMS tanılı hastanın %25’inde DMF başlandıktan sonraki takip döneminde NEDA-3 durumu sağlandığı görüldü. DMF öncesinde EDSS skorunun 3’ün altında olması NEDA-3 durumunun yitimine, ilk atağa ve ilk özürlülük birikiminin olmasına kadar geçen süreleri anlamlı ölçüde uzattı (NEDA-3 için p=0,008, HR=1,95).
Sonuç: Çalışmamızda elde edilen gerçek yaşam verileri güncel bilgiler ile büyük oranda benzerlik göstermektedir. Elde ettiğimiz bulgular EDSS skoru 3’ün altında olan hastalarda başlanan DMF’nin atak, yeni beyin MRG lezyonu ve engellilik birikimi gelişme riskinin azalttığına işaret etmektedir.

Anahtar Kelimeler

Multipl Skleroz, dimetil fumarat, Nöroimmünomodülasyon, Gerçek Yaşam Çalışması

Kaynakça

• Valencia-Sanchez C, Carter JL. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis. Expert Opin Pharmacother. 2020;21(12):1399-1405. doi:10.1080/14656566.2020.1763304
• Gold R, Kappos L, Arnold DL, et al. Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis. NEJM 2012;367(12):1098-1107. doi:10.1056/NEJMoa1114287
• Bar-Or A, Gold R, Kappos L, et al. Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of the DEFINE study. Journal of Neurology. 2013;260(9):2297-2305. doi:10.1007/s00415-013-6954-7
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. NEJM. 20 2012;367(12):1087-97. doi:10.1056/NEJMoa1206328
• TECFIDERA prescribing information (2013).
• Lorscheider J, Benkert P, Lienert C, et al. Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis. J Neurol. 2021;268(3):941-949. doi:10.1007/s00415-020-10226-6
• Liang G, Chai J, Ng HS, Tremlett H. Safety of dimethyl fumarate for multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2020;46:102566. doi:10.1016/j.msard.2020.102566
• Trojano M, Tintore M, Montalban X, et al. Treatment decisions in multiple sclerosis - insights from real-world observational studies. Nature Reviews Neurology. 2017;13(2):105-118. doi:10.1038/nrneurol.2016.188
• Klonoff DC. The Expanding Role of Real-World Evidence Trials in Health Care Decision Making. J Diabetes Sci Technol. 2020;14(1):174-179. doi:10.1177/1932296819832653
• Barros A, Sequeira J, de Sousa A, et al. Real-Word Effectiveness and Safety of Dimethyl Fumarate in a Multiple Sclerosis Portuguese Population. Clin Neuropharmacol. 2020;43(3):55-60. doi:10.1097/wnf.0000000000000391
• Condé S, Moisset X, Pereira B, et al. Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study. Eur J Neurol. 2019;26(3):460-467. doi:10.1111/ene.13839
• Kalincik T, Kubala Havrdova E, Horakova D, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2019;90(4):458-468. doi:10.1136/jnnp-2018-319831
• Lanzillo R, Moccia M, Palladino R, et al. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study. Mult Scler Relat Disord. Feb 2020;38:101871. doi:10.1016/j.msard.2019.101871
• Laplaud DA, Casey R, Barbin L, et al. Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology. 2019;93(7):e635-e646. doi:10.1212/wnl.0000000000007938
• Sabin J, Urtiaga S, Pilo B, et al. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population. J Neurol 2020;267(8):2362-2371. doi:10.1007/s00415-020-09848-7
• Sejbaek T, Nybo M, Petersen T, Illes Z. Real-life persistence and tolerability with dimethyl fumarate. Mult Scler Relat Disord. 2018;24:42-46. doi:10.1016/j.msard.2018.05.007
• Mallucci G, Annovazzi P, Miante S, et al. Two-year real-life efficacy, tolerability and safety of dimethyl fumarate in an Italian multicentre study. J Neurol. 2018;265(8):1850-1859. doi:10.1007/s00415-018-8916-6
• Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Multiple Sclerosis. 2017;23(9):1233-1240. doi:10.1177/1352458516675039
• Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133(7):1900-1913. doi:10.1093/brain/awq076